Skip to content

Effect of a Plant-based Ingredient on Glucose Response

An Exploratory Study of a Plant-based Ingredient for Reducing the Post-prandial Blood Glucose Response in Healthy Indian Adults, When Administered With a Meal

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02218528
Enrollment
48
Registered
2014-08-18
Start date
2014-08-31
Completion date
2014-09-30
Last updated
2015-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

subjects

Brief summary

The study is designed to determine the extent to which a plant-based ingredient is able to modulate blood glucose response when administered with a meal.

Interventions

DIETARY_SUPPLEMENTPlant-based ingredient
DIETARY_SUPPLEMENTNo Plant-based ingredient

Sponsors

Unilever R&D
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy males and females, age at start of the study ≥ 18 and ≤ 50 years; * Apparently healthy: no medical conditions which might affect the study measurements, as judged by study physician and/or measured by questionnaire, and/or assessed by haematology, blood chemistry and urinalysis; * Fasting blood glucose value of subjects is ≥ 3.4 and ≤ 6.1 mmol/litre (i.e. 62-110 mg/dl) at screening; * Haemoglobin level within clinically acceptable range (for male 12 to 17 gm/dL and for females 11 to 15 gm/dL; both inclusive) as judged by the research physician; * Body mass index (BMI) ≥ 18,0 and ≤ 25,0 kg/m2; * Agreeing to be informed about medically relevant personal test-results by study physician; * Willing to comply to study protocol during study; * Willing to refrain from drinking of alcohol on and one day before the blood withdrawal; * Accessible veins on arms as determined by examination at screening; * Being literate; * HbA1C ≤ 6.5 % (48 mmol/mol).

Exclusion criteria

* Any history of diabetes, hyper- (or hypo-) glycemia or other disorder of glucose metabolism; * Any history of gastro-intestinal disorders (including frequent diarrhoea for example); * Blood donation in the past 2 months; * Reported participation in another nutritional or biomedical trial 3 months before the pre-study examination or during the study; * Reported participation in night shift work two weeks prior to pre-study investigation or during the study. Night work is defined as working between 23.00 PM and 6.00 AM; * Reported intense sporting activities \> 10h/w; * Consumption of ≥120 ml of alcoholic drinks for males and females in a typical week; * Drug abuse as indicated by urine analysis; * Chronic smokers, tobacco chewers and drinkers; * Use of any medication, including supplements and traditional medicine; * Reported dietary habits, such as a medically prescribed/slimming diet; * Not being used to eat breakfast; * Reported weight loss/gain (\>10%) in the last six month before the study; * Being an employee of Unilever or CRO; * Allergy or intolerance to food products and aversion to food products provided during the study; * If female: pregnant or will be planning pregnancy during the study period; * If female: lactating or has been lactating in the 6 weeks before pre-study investigation and/or during the study period.

Design outcomes

Primary

MeasureTime frame
Positive incremental post-prandial blood glucose area unde the curve120 minutes

Secondary

MeasureTime frameDescription
Positive incremental post-prandial blood glucose area under the curve180 minutes
Post-prandial insulin response120 minutes
Assessment of gastric emptying rate10 hoursGE50% (time to empty 50% of the gastric content) will be determined with paracetamol

Other

MeasureTime frameDescription
Cmax-baseline corrected120 minutespeak plasma glucose - baseline plasma glucose
Tmax120 minutespeak time plasma glucose
Cmax120 minutespeak plasma glucose

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026